TG Therapeutics, Inc.
NCM: TGTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes TG Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TGTX Z-Score →About TG Therapeutics, Inc.
Healthcare
Biotechnology
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
📊 Fundamental Analysis
TG Therapeutics, Inc. demonstrates exceptional profitability, with a profit margin of 72.6%.
The company recently reported 78.0% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 102.8%, which reflects exceptional capital efficiency.
At a current price of $33.73, TGTX currently sits at the 40th percentile of its 52-week range (Range: $25.28 - $46.48).
💰 Valuation Insight
TGTX trades at a 51.3% discount (PE: 12.18), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$5.39B
Trailing P/E
12.18
Forward P/E
13.70
Beta (5Y)
1.75
52W High
$46.48
52W Low
$25.28
Avg Volume
2.02M
Day High
Day Low